BNB Plus announced that following a strategic restructuring and realignment of resources implemented earlier this year, its LineaRx subsidiary has significantly reduced its costs. Based on its reduced costs and an increase in customer shipments, the company expects LineaRx to significantly narrow its losses for Q1 2026 and approach profitability. Management views this milestone as a clear validation of its strategic realignment and believes it positions LineaRx to add accretive value beyond the company’s digital asset treasury strategy.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNBX: